Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

2.45USD
22 Jun 2018
Change (% chg)

$0.08 (+3.38%)
Prev Close
$2.37
Open
$2.25
Day's High
$2.45
Day's Low
$2.25
Volume
10,786
Avg. Vol
17,132
52-wk High
$3.45
52-wk Low
$1.35

Select another date:

Tue, May 15 2018

BRIEF-Imprimis Pharmaceuticals Q1 Revenue Rose 45 Pct To $8.9 Million

* IMPRIMIS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 RESULTS

BRIEF-Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing From Flying L Partners

* SURFACE PHARMACEUTICALS, INC. ANNOUNCES $20 MILLION SERIES A FINANCING FROM FLYING L PARTNERS

BRIEF-Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation

* IMPRIMIS PHARMACEUTICALS ISSUED COMPOSITION PATENT FOR NON-OPIOID CONSCIOUS SEDATION FORMULATION

BRIEF-Imprimis Pharmaceuticals Q4 Revenue $7.3 Million

* IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS

BRIEF-Imprimis Pharma Makes Available Two Glaucoma Drugs On FDA's Drug Shortage List

* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:

BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

Select another date: